RT-PCR versus immunohistochemistry for correlation and quantification of ERCC1, BRCA1, TUBB3 and RRM1 in NSCLC

Lung Cancer

Volumn 75, Issue 3, 2012, Pages 306-312

  Vilmar, A ^a,b   Garcia Foncillas, J ^b   Huarriz, M ^b   Santoni Rugiu, E ^c   Sorensen, J B ^a  

^a FINSEN LABORATORY   (Denmark)

^b UNIVERSITY OF NAVARRA   (Spain)

^c Rigshospitalet   (Denmark)

Author keywords

Advanced NSCLC; Immunohistochemical analysis; Methodology; Predictive biomarkers; QRT PCR

Indexed keywords

BETA TUBULIN; BRCA1 PROTEIN; CISPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEMCITABINE; MESSENGER RNA; PACLITAXEL; RIBONUCLEOTIDE REDUCTASE; RIBONUCLEOTIDE REDUCTASE M1; UNCLASSIFIED DRUG; VINORELBINE DITARTRATE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CANCER TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRCA1 PROTEIN; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; DNA-BINDING PROTEINS; ENDONUCLEASES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUBULIN; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS; YOUNG ADULT;

EID: 84856577873     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.08.016     Document Type: Article

References (31)

1. Ref Type: Generic. http://seer.cancer.gov/statfacts/html/lungb.html.
2. Ardizzoni A., Boni L., Tiseo M., Fossella F.V., Schiller J.H., Paesmans M., et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 2007, 99(11):847-857.
3. Mitsudomi T., Morita S., Yatabe Y., Negoro S., Okamoto I., Tsurutani J., et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010, 11(2):121-128.
4. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361(10):947-957.
5. Cobo M., Isla D., Massuti B., Montes A., Sanchez J.M., Provencio M., et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol 2007, 25(19):2747-2754.
6. Olaussen K.A., Dunant A., Fouret P., Brambilla E., Andre F., Haddad V., et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006, 355(10):983-991.
7. Vilmar A.C., Santoni-Rugiu E., Sorensen J.B. ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial. Ann Oncol 2010, 21(9):1817-1824.
8. de Laat W.L., Jaspers N.G., Hoeijmakers J.H. Molecular mechanism of nucleotide excision repair. Genes Dev 1999, 13(7):768-785.
9. Cummings M., Higginbottom K., McGurk C.J., Wong O.G., Koberle B., Oliver R.T., et al. XPA versus ERCC1 as chemosensitising agents to cisplatin and mitomycin C in prostate cancer cells: role of ERCC1 in homologous recombination repair. Biochem Pharmacol 2006, 72(2):166-175.
10. Wijnhoven S.W., Hoogervorst E.M., de W.H., van der Horst G.T., van S.H. Tissue specific mutagenic and carcinogenic responses in NER defective mouse models. Mutat Res 2007, 614(1-2):77-94.
11. Martin R.W., Connell P.P., Bishop D.K. The Yin and Yang of treating BRCA-deficient tumors. Cell 2008, 132(6):919-920.
12. Bhattacharya A., Ear U.S., Koller B.H., Weichselbaum R.R., Bishop D.K. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem 2000, 275(31):23899-23903.
13. Taron M., Rosell R., Felip E., Mendez P., Souglakos J., Ronco M.S., et al. BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Genet 2004, 13(20):2443-2449.
14. Quinn J.E., James C.R., Stewart G.E., Mulligan J.M., White P., Chang G.K., et al. BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy. Clin Cancer Res 2007, 13(24):7413-7420.
15. Rosell R., Danenberg K.D., Alberola V., Bepler G., Sanchez J.J., Camps C., et al. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 2004, 10(4):1318-1325.
16. Bepler G., Kusmartseva I., Sharma S., Gautam A., Cantor A., Sharma A., et al. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J Clin Oncol 2006, 24(29):4731-4737.
17. Ceppi P., Volante M., Novello S., Rapa I., Danenberg K.D., Danenberg P.V., et al. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol 2006, 17(12):1818-1825.
18. Jordan M.A., Toso R.J., Thrower D., Wilson L. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci USA 1993, 90(20):9552-9556.
19. Seve P., Isaac S., Tredan O., Souquet P.J., Pacheco Y., Perol M., et al. Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy. Clin Cancer Res 2005, 11(15):5481-5486.
20. Burkhart C.A., Kavallaris M., Band H.S. The role of beta-tubulin isotypes in resistance to antimitotic drugs. Biochim Biophys Acta 2001, 1471(2):O1-O9.
21. Seve P., Mackey J., Isaac S., Tredan O., Souquet P.J., Perol M., et al. Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol Cancer Ther 2005, 4(12):2001-2007.
22. Booton R., Ward T., Ashcroft L., Morris J., Heighway J., Thatcher N. ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer. J Thorac Oncol 2007, 2(10):902-906.
23. Wachters F.M., Wong L.S., Timens W., Kampinga H.H., Groen H.J. ERCC1, hRad51, and BRCA1 protein expression in relation to tumour response and survival of stage III/IV NSCLC patients treated with chemotherapy. Lung Cancer 2005, 50(2):211-219.
24. Zheng Z., Chen T., Li X., Haura E., Sharma A., Bepler G. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 2007, 356(8):800-808. 22.
25. Kashima K., Oite T., Aoki Y., Takakuwa K., Aida H., Nagata H., et al. Screening of BRCA1 mutation using immunohistochemical staining with C-terminal and N-terminal antibodies in familial ovarian cancers. Jpn J Cancer Res 2000, 91(4):399-409.
26. Eikmans M., Baelde H.J., de H.E., Bruijn J.A. Messenger RNA assessment in clinical nephrology: perspectives and progress of methodology. Nephrol Dial Transplant 2005, 20(12):2598-2601.
27. Votavova H., Forsterova K., Stritesky J., Velenska Z., Trneny M. Optimized protocol for gene expression analysis in formalin-fixed, paraffin-embedded tissue using real-time quantitative polymerase chain reaction. Diagn Mol Pathol 2009, 18(3):176-182.
28. Britten R.A., Liu D., Tessier A., Hutchison M.J., Murray D. ERCC1 expression as a molecular marker of cisplatin resistance in human cervical tumor cells. Int J Cancer 2000, 89(5):453-457.
29. Doll C.M., Prystajecky M., Eliasziw M., Klimowicz A.C., Petrillo S.K., Craighead P.S., et al. Low ERCC1 mRNA and protein expression are associated with worse survival in cervical cancer patients treated with radiation alone. Radiother Oncol 2010, 97(2):352-359.
30. De Castro G., Pasini F.S., Siqueira S.A., Ferraz A.R., Villar R.C., Snitcovsky I.M., et al. ERCC1 protein, mRNA expression and T19007C polymorphism as prognostic markers in head and neck squamous cell carcinoma patients treated with surgery and adjuvant cisplatin-based chemoradiation. Oncol Rep 2011, 25(3):693-699.
31. de Bruin E.C., van de P.S., Lips E.H., van E.R., van der Zee M.M., Lombaerts M., et al. Macrodissection versus microdissection of rectal carcinoma: minor influence of stroma cells to tumor cell gene expression profiles. BMC Genomics 2005, 6:142.